Apolipoprotein B

Biomarker

Related News

Oral PCSK9 Inhibitor Enlicitide Reduces LDL Cholesterol in Phase 3 Trial

Mar 05, 2026

Enlicitide decanoate demonstrated efficacy in reducing LDL cholesterol levels compared to placebo in patients with atherosclerotic cardiovascular disease history or risk, according to phase 3 CORALreef Lipids trial data.

Oral Cholesterol Drug Enlicitide Reduces LDL by 60% in Phase 3 Trial

Feb 16, 2026

A phase three clinical trial shows enlicitide, an oral monoclonal antibody, reduced LDL cholesterol by 60% compared to placebo in 2,909 patients with or at risk of atherosclerosis over 24 weeks.